Mesirow Financial Investment Management Inc. Decreases Position in Bristol Myers Squibb Company $BMY

Mesirow Financial Investment Management Inc. lowered its position in Bristol Myers Squibb Company (NYSE:BMY) by 34.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,006 shares of the biopharmaceutical company’s stock after selling 15,539 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Bristol Myers Squibb were worth $1,389,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Simon Quick Advisors LLC lifted its stake in Bristol Myers Squibb by 19.8% in the second quarter. Simon Quick Advisors LLC now owns 14,788 shares of the biopharmaceutical company’s stock valued at $685,000 after buying an additional 2,440 shares during the last quarter. Strs Ohio lifted its stake in Bristol Myers Squibb by 8.0% in the second quarter. Strs Ohio now owns 642,853 shares of the biopharmaceutical company’s stock valued at $29,758,000 after buying an additional 47,591 shares during the last quarter. Impact Partnership Wealth LLC lifted its stake in Bristol Myers Squibb by 91.1% in the second quarter. Impact Partnership Wealth LLC now owns 27,096 shares of the biopharmaceutical company’s stock valued at $1,254,000 after buying an additional 12,917 shares during the last quarter. Amalgamated Bank lifted its stake in Bristol Myers Squibb by 3.1% in the second quarter. Amalgamated Bank now owns 413,448 shares of the biopharmaceutical company’s stock valued at $19,139,000 after buying an additional 12,577 shares during the last quarter. Finally, Savvy Advisors Inc. lifted its stake in Bristol Myers Squibb by 68.3% in the second quarter. Savvy Advisors Inc. now owns 46,410 shares of the biopharmaceutical company’s stock valued at $2,148,000 after buying an additional 18,835 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.09% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BMY. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective for the company. in a research note on Tuesday, August 5th. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Finally, Daiwa America cut Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fourteen have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $57.23.

Bristol Myers Squibb Trading Up 1.0%

Shares of BMY stock opened at $46.10 on Friday. The business’s fifty day moving average price is $45.34 and its 200 day moving average price is $46.82. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The firm has a market capitalization of $93.82 billion, a PE ratio of 18.59, a P/E/G ratio of 2.23 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the prior year, the company posted $1.80 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.4%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is currently 100.00%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.